N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Sponsor: Pfizer • ClinicalTrials.gov ID: NCT06462235

Registry updated: 2026-10-15
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria. The study medicine is a combination of an antibiotic, aztreonam (ATM), and another medicine, avibactam (AVI), which is used to help stop bacteria from being resistant to antibiotics. Antibiotics are medicines that fights bacteria and infections. The study will include newborns and infants up to 9 months of age who are admitted in the hospital. The study is conducted in 2 parts: Part A and Part B. In Part A, all participants will receive a single intravenous (injected directly into a vein) infusion of ATM-AVI. This is to study the safety and effects of a single amount. In Part B, all participants will receive multiple intravenous infusions of ATM-AVI as treatment for a possible or confirmed infection with gram-negative bacteria.

Interventions

  • Part A: ATM-AVI Single Dose, Cohorts 1-4 (Drug)
    Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.
  • Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (Drug)
    Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.

Eligibility criteria

Inclusion Criteria Participants must meet the following key inclusion criteria to be eligible for enrollment into the study: 1. Hospitalized with age from birth \<9 months, including preterm birth 2. Part A: Receiving IV antibiotics for treatment of suspected or confirmed bacterial infection, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis. 3. Part B: Suspected or confirmed gram-negative bacterial infection requiring IV antibiotics, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis. Participants with any of the following characteristics/conditions will be excluded: 1. Received any other investigational medicinal product within the longer of 30 days or 5 half-lives before enrollment. 2. Any medical or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 3. Severe renal impairment or known significant renal disease, as evidenced by elevated serum creatinine at screening, or urinary output \<0.5 mL/kg/h for 6 consecutive hours or requirement for dialysis. 4. Part B Only: Received \>24 hours of systemic antibiotic treatment for gram-negative organisms at time of enrollment, unless documented treatment failure or lack of improvement in at least one objective sign or symptom of infection after ≥48 hours of antibiotics.

Conditions

Gram-negative Bacterial Infection

Locations

  • Children's Hospital of Orange County Southwest Tower — Orange, California, United States
  • Children's Hospital of Orange County — Orange, California, United States
  • Children's Hospital Colorado — Aurora, Colorado, United States
  • Riley Hospital for Children at Indiana University Health — Indianapolis, Indiana, United States
  • Norton Children's Hospital — Louisville, Kentucky, United States
  • Novak Center for Children's Health — Louisville, Kentucky, United States
  • University of Louisville, Norton Children's Research Institute — Louisville, Kentucky, United States
  • Tufts Medical Center — Boston, Massachusetts, United States
  • Duke University - Main Hospital and Clinics — Durham, North Carolina, United States
  • Memorial Hermann Hospital - Texas Medical Center — Houston, Texas, United States
  • The University of Texas Health Science Center at Houston — Houston, Texas, United States
  • Sanatorio Sagrado Corazón — Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • Clinica Del Niño Y La Madre — Mar del Plata, Buenos Aires, Argentina
  • Clinica Privada del Sol S.A — Córdoba, Córdoba Province, Argentina
  • Hospital del Niño Jesús — San Miguel de Tucumán, Tucumán Province, Argentina
  • UMHAT Deva Maria — Burgas, Bulgaria
  • Umhat Kanev — Rousse, Bulgaria
  • Ippokrateio General Hospital of Thessaloniki — Thessaloniki, Kentrikí Makedonía, Greece
  • Nirmal Hospital Pvt Ltd. — Surat, Gujarat, India
  • RajaRajeswari Medical College and Hospital — Bengaluru, Karnataka, India
  • Sahyadri Super Speciality Hospital — Pune, Maharashtra, India
  • Medanta Hospital Lucknow — Lucknow, Uttar Pradesh, India
  • Institute of Child Health — Kolkata, West Bengal, India
  • Schneider Children's Medical Center — Petah Tikva, Central District, Israel
  • Rambam Health Care Campus — Haifa, Northern District, Israel
  • Azienda Ospedaliera Universitaria Meyer IRCCS — Florence, Florence, Italy
  • Hospital Universitario La Paz — Madrid, Madrid, Comunidad de, Spain
  • Hospital Universitario 12 de Octubre — Madrid, Spain
  • Hsinchu Municipal Mackay Children's Hospital — Hsinchu, Hsinchu, Taiwan
  • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation — Hualien City, Hualien, Taiwan
  • Taichung Veterans General Hospital — Taichung, Taiwan
  • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital — Taoyuan, Taiwan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record